MEIP : Summary for MEI Pharma, Inc. - Yahoo Finance

U.S. Markets closed

MEI Pharma, Inc. (MEIP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.71+0.02 (+1.18%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1.69
Bid1.45 x 800
Ask2.27 x 100
Day's Range1.65 - 1.72
52 Week Range1.13 - 2.28
Avg. Volume298,043
Market Cap62.88M
PE Ratio (TTM)-16.93
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Accesswire2 months ago

    Post Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta

    Upcoming AWS Coverage on MEI Pharma Post-Earnings Results LONDON, UK / ACCESSWIRE / December 27, 2016 / Active Wall St. announces its post-earnings coverage on Summit Therapeutics PLC (NASDAQ: SMMT). The ...

  • How MEI Pharma Inc (MEIP) Stacks Up Against Its Peers
    Insider Monkey2 months ago

    How MEI Pharma Inc (MEIP) Stacks Up Against Its Peers

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. The Standard and Poor’s 500 Index returned 7.6% over […]

  • PR Newswire3 months ago

    Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

    LUGANO, Switzerland, and SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced final results from a Phase 2 clinical study of the investigational drug candidate Pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) who were not eligible for induction chemotherapy, including evidence of prolongation of survival in the overall population and across a number of patient subgroups. In an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Saturday, Dr. Guillermo Garcia-Manero, MD Anderson Cancer Center, principal investigator of the study, reported a median overall survival of 19.1 (95%CI: 10.7-26.5) months, one-year survival of 62% and a complete response (CR) rate of 42%.